Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Existing studies suggest a quality gap with respect to end-of-life (EOL) care for patients with blood cancers,1 and less timely EOL discussions may be partly to blame. Indeed, patients with blood cancers are more likely to receive chemotherapy and be hospitalized when near death, to die in acute care settings, and are less likely to use hospice services than those with advanced solid tumors.1 A rigorous understanding of when EOL discussions occur for patients with hematologic cancers is a necessary step toward developing targeted interventions to improve the quality of their EOL care.
Odejide OO, Cronin AM, Condron N, Earle CC, Wolfe J, Abel GA. Timeliness of End-of-Life Discussions for Blood CancersA National Survey of Hematologic Oncologists. JAMA Intern Med. 2016;176(2):263-265. doi:10.1001/jamainternmed.2015.6599